AU2011292119B2 - Anti-cancer adenoviruses - Google Patents

Anti-cancer adenoviruses Download PDF

Info

Publication number
AU2011292119B2
AU2011292119B2 AU2011292119A AU2011292119A AU2011292119B2 AU 2011292119 B2 AU2011292119 B2 AU 2011292119B2 AU 2011292119 A AU2011292119 A AU 2011292119A AU 2011292119 A AU2011292119 A AU 2011292119A AU 2011292119 B2 AU2011292119 B2 AU 2011292119B2
Authority
AU
Australia
Prior art keywords
orf3
cells
infected
carcinoma
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011292119A
Other languages
English (en)
Other versions
AU2011292119A1 (en
Inventor
Clodagh O'shea
Colin Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU2011292119A1 publication Critical patent/AU2011292119A1/en
Application granted granted Critical
Publication of AU2011292119B2 publication Critical patent/AU2011292119B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2011292119A 2010-08-16 2011-08-16 Anti-cancer adenoviruses Active AU2011292119B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (2)

Publication Number Publication Date
AU2011292119A1 AU2011292119A1 (en) 2013-02-28
AU2011292119B2 true AU2011292119B2 (en) 2015-06-11

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011292119A Active AU2011292119B2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Country Status (10)

Country Link
US (1) US9187733B2 (enExample)
EP (1) EP2606137B1 (enExample)
JP (1) JP5905460B2 (enExample)
KR (1) KR101667094B1 (enExample)
CN (1) CN103180448B (enExample)
AU (1) AU2011292119B2 (enExample)
BR (1) BR112013003579A2 (enExample)
CA (1) CA2807778C (enExample)
SG (1) SG187785A1 (enExample)
WO (1) WO2012024350A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
CA2867129C (en) * 2012-03-13 2023-11-21 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2837400T3 (es) 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
DK1199368T3 (da) * 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
EP1284294A4 (en) * 2000-05-26 2004-10-13 Sumitomo Pharma RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01)
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
WO2005048950A2 (en) 2003-11-17 2005-06-02 Biomune, Inc. Tumor and infectious disease therapeutic compositions
EP2352516A2 (en) * 2008-09-26 2011-08-10 Auburn University Immunization of avians by mucosal administration of non-replicating vectored vaccines
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Goodrum FD et al, Journal of Virology, 1999, 73(9):7474-88. *
Shepard RN et al, Journal of Virology, 2003, 77(15):8593-5 *
Shepard RN et al, Journal of Virology, 2004, 78(18):9924-35 *

Also Published As

Publication number Publication date
WO2012024350A3 (en) 2012-07-05
US20130243729A1 (en) 2013-09-19
SG187785A1 (en) 2013-03-28
EP2606137A2 (en) 2013-06-26
EP2606137B1 (en) 2018-08-01
US9187733B2 (en) 2015-11-17
KR101667094B1 (ko) 2016-10-17
CA2807778C (en) 2017-03-07
JP2013537426A (ja) 2013-10-03
JP5905460B2 (ja) 2016-04-20
WO2012024350A2 (en) 2012-02-23
CA2807778A1 (en) 2012-02-23
CN103180448A (zh) 2013-06-26
CN103180448B (zh) 2017-04-12
BR112013003579A2 (pt) 2016-06-07
EP2606137A4 (en) 2014-01-08
AU2011292119A1 (en) 2013-02-28
KR20130126590A (ko) 2013-11-20

Similar Documents

Publication Publication Date Title
AU2011292119B2 (en) Anti-cancer adenoviruses
CA2903582C (en) Oncolytic adenovirus compositions
Li et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo
KR100379174B1 (ko) DNA손상제및p53을포함하는조성물
Fujiwara et al. Enhanced antitumor efficacy of telomerase‐selective oncolytic adenoviral agent OBP‐401 with docetaxel: preclinical evaluation of chemovirotherapy
WO2013138505A1 (en) Selective cell targeting using adenovirus and chemical dimers
US20090202489A2 (en) Adenoviruses mutated in the va genes for cancer treatment
Schipper et al. Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus
Nie et al. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system
Lee et al. Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo.
Roth et al. Gene replacement strategies for treating non-small cell lung cancer
Kaliberova et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma
Yoo et al. Vaccinia virus‐mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP
Chen et al. Advancing lung cancer treatment with combined c-met promoter-driven oncolytic adenovirus and rapamycin
Chen et al. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo
Graumann Studies on biodistribution and pharmacokinetics of capsid-modified adenoviral vectors
TWI391486B (zh) 新穎啟動子及包含其之病毒載體
US20070081978A1 (en) Adeno-associated virus-mediated survivin mutants and methods related thereto
van den Wollenberg Characterization of a replicating expanded-tropism oncolytic
Kallin Screening of pancreatic cancer cell lines with oncolytic adenovirus Ad5ΔE1ACR2ΔE1B19k (Ad5ΔΔ) in combination with chemotherapeutics
WO2014201283A1 (en) Methods for protecting ovarian function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)